ClinicalTrials.gg
CompletedNCT03339752Updated Dec 11, 2017

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin

A Phase 1 interventional study of Rosuvastatin and ACT-541468 in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Czechia. Open to male participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-11.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
Male
01

Study summary

A study in healthy male subjects to investigate whether administration of ACT-541468 can affect the fate in the body (amount and time of presence in the blood) of rosuvastatin

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed in the local language prior to any study mandated procedure;
  • Healthy male subjects aged 18 to 45 years (inclusive) at screening;
  • of 18.0 to 28.0 kg/m2 (inclusive) at screening;
  • Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • Known allergic reactions or to ACT-541468, rosuvastatin, any drug of the same classes, or any of their ;
  • Any for rosuvastatin treatment;
  • History or clinical evidence of myopathy;
  • Asian or Indian-Asian ethnicity;
  • Known hypersensitivity or allergy to natural rubber latex;
  • Previous exposure to ACT-541468;
  • Treatment with rosuvastatin within 3 months prior to screening;
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Treatment A

    Rosuvastatin Day 1

    Drug: Rosuvastatin

  • Experimental
    Treatment B1

    ACT-541468 Day 5 to Day 7

    Drug: ACT-541468

  • Other
    Treatment B2

    Rosuvastatin Day 8; ACT-541468 Day 8 to Day 12

    Drug: Rosuvastatin · Drug: ACT-541468

Interventions

06

What researchers measure

Primary outcomes

  1. Effect of ACT-541468 at steady-state on Cmax of single-dose rosuvastatin

    Effect of ACT-541468 at steady-state on Cmax of single-dose rosuvastatin

    Time frame: During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.

  2. Effect of ACT-541468 at steady-state on tmax of single-dose rosuvastatin

    Effect of ACT-541468 at steady-state on tmax of single-dose rosuvastatin

    Time frame: During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.

  3. Effect of ACT-541468 at steady-state on AUC0-t of single-dose rosuvastatin

    Effect of ACT-541468 at steady-state on AUC0-t of single-dose rosuvastatin

    Time frame: During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.

  4. Effect of ACT-541468 at steady-state on AUC0-∞ of single-dose rosuvastatin

    Effect of ACT-541468 at steady-state on AUC0-∞ of single-dose rosuvastatin

    Time frame: During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.

  5. Effect of ACT-541468 at steady-state on t½ of single-dose rosuvastatin

    Effect of ACT-541468 at steady-state on t½ of single-dose rosuvastatin

    Time frame: During administration of rosuvastatin (Treatment A) and both rosuvastatin and ACT-541468 (Treatment B2); i.e. for about 2 weeks.

Secondary outcomes

  1. Trough concentration (Ctrough) of ACT-541468

    Trough concentration (Ctrough) of ACT-541468

    Time frame: During ACT-541468 administration (Treatment B1 and B2); i.e. for about 1 week

  2. Change in vital signs

    Change from baseline to each time point of measurement during each treatment in vital signs (supine BP and pulse rate)

    Time frame: From Screening to EOS (for a maximum of up to 5 weeks)

  3. Change in ECG variables

    Change from baseline to each time point of measurement during each treatment in ECG variables

    Time frame: From Screening to EOS (for a maximum of up to 5 weeks)

  4. Treatment-emergent (serious) adverse events

    Treatment-emergent AEs and SAEs during each treatment

    Time frame: From Screening to EOS (for a maximum of up to 5 weeks)

  5. Treatment-emergent ECG abnormalities

    Treatment-emergent ECG abnormalities during each treatment

    Time frame: From Screening to EOS (for a maximum of up to 5 weeks)

  6. Change in body weight

    Change from baseline to each time point of measurement during each treatment in body weight

    Time frame: From Screening to EOS (for a maximum of up to 5 weeks)

  7. Change in clinical laboratory tests

    Change from baseline to each time point of measurement during each treatment in clinical laboratory tests

    Time frame: From Screening to EOS (for a maximum of up to 5 weeks)

07

Study locations

1 site
  • Cepha s.r.o.
    Pilsen, 32300, Czechia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Dec 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Nov 13, 2017
StartActual
Oct 30, 2017
Primary completionActual
Dec 2, 2017
CompletionActual
Dec 2, 2017
Last update
Dec 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03339752
Responsible party
Sponsor
First posted
Nov 13, 2017
Start date
Oct 30, 2017
Primary completion
Dec 2, 2017
Completion
Dec 2, 2017
Last update
Dec 11, 2017

Study contacts

Clemens Mühlan
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daridorexant

Start the discussion